Blueprint Medicines

The first half of 2025 witnessed unprecedented M&A activity with major deals including Merck's $3.9 billion SpringWorks acquisition, Sanofi's $9.5 billion Blueprint Medicines purchase, and Johnson & Johnson's $14.6 billion Intra-Cellular Therapies acquisition.

Isomorphic Labs, the AI-first drug discovery company, has appointed Dr. Ben Wolf as Chief Medical Officer to lead translation of AI-driven discoveries into clinical medicines.

ANGLE presented breakthrough data at EACR 2025 demonstrating DNA dual analysis combining CTC-DNA and ctDNA from single blood samples, revealing 53% of mutations found exclusively in CTCs in lung cancer patients.

The FDA has deployed an internal AI tool called "Elsa" to enhance regulatory processes for drug and medical device reviews, though the system reportedly struggles with error correction.

Sanofi will acquire Blueprint Medicines Corporation for $129.00 per share in cash, representing an equity value of approximately $9.1 billion, with additional contingent value rights potentially worth $9.5 billion total.

VantAI and Blueprint Medicines have expanded their strategic collaboration for the second time since 2022, incorporating additional drug programs focused on targets previously considered undruggable.

Pharmaceutical M&A activity is experiencing a significant rebound with major deals including Novartis's $1.7 billion acquisition of Regulus Therapeutics and Merck KGaA's $3.9 billion purchase of SpringWorks Therapeutics.

Eli Lilly's Retevmo (selpercatinib) receives FDA approval as the first targeted therapy for RET-altered lung and thyroid cancers, demonstrating response rates up to 84% in clinical trials.

Blueprint Medicines reports promising Phase 1 data for BLU-808, demonstrating favorable pharmacokinetics supporting once-daily dosing in healthy volunteers.

Blueprint Medicines projects a $4 billion peak revenue opportunity for its systemic mastocytosis (SM) franchise, driven by AYVAKIT's success and updated SM prevalence estimates.